The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cetuximab metastatic colorectal cancer strategy (ERMES) study: A phase III randomized two arm study with FOLFIRI + cetuximab until disease progression compared to FOLFIRI + cetuximab for 8 cycles followed by cetuximab alone until disease progression in first-line treatment of patients with RAS and BRAF wild type metastatic colorectal cancer.
 
Carmine Pinto
No Relationships to Disclose
 
Nicola Normanno
No Relationships to Disclose
 
Armando Orlandi
No Relationships to Disclose
 
Evaristo Maiello
No Relationships to Disclose
 
Domenico Bilancia
No Relationships to Disclose
 
Domenico C. Corsi
No Relationships to Disclose
 
Emiliano Tamburini
No Relationships to Disclose
 
Salvatore Pisconti
No Relationships to Disclose
 
Francesco Ferraú
No Relationships to Disclose
 
Francesco Di Costanzo
No Relationships to Disclose
 
Stefania Gori
No Relationships to Disclose
 
Bruno Daniele
No Relationships to Disclose
 
Giuseppe Tonini
No Relationships to Disclose
 
Alberto Zaniboni
No Relationships to Disclose
 
Hector Soto-parra
No Relationships to Disclose
 
Giovanni Luca Frassinetti
No Relationships to Disclose
 
Rosario Vincenz Iaffaioli
No Relationships to Disclose
 
M. Giulia Zampino
No Relationships to Disclose
 
Lazzaro Repetto
No Relationships to Disclose
 
Carlo Antonio Barone
No Relationships to Disclose